NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis $4.66 +0.37 (+8.62%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.35▼$4.7750-Day Range$3.32▼$5.0952-Week Range$1.64▼$5.34Volume12.88 million shsAverage Volume11.34 million shsMarket Capitalization$2.76 billionP/E RatioN/ADividend YieldN/APrice Target$6.93 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Geron alerts: Email Address Geron MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside48.7% Upside$6.93 Price TargetShort InterestHealthy7.53% of Shares Sold ShortDividend StrengthN/ASustainability-2.80Upright™ Environmental ScoreNews Sentiment0.59Based on 18 Articles This WeekInsider TradingSelling Shares$6.81 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.35) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.36 out of 5 starsMedical Sector139th out of 936 stocksPharmaceutical Preparations Industry56th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGeron has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Geron's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.53% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Geron has recently decreased by 5.08%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGeron has received a -34.47% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Geron is -2.80. Previous Next 2.0 News and Social Media Coverage News SentimentGeron has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Geron this week, compared to 4 articles on an average week.Search InterestOnly 27 people have searched for GERN on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.MarketBeat FollowsOnly 22 people have added Geron to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,808,004.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Geron's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 10.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Geron's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Geron Stock (NASDAQ:GERN)Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More GERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERN Stock News HeadlinesJuly 11, 2024 | insidertrades.comGeron Co. (NASDAQ:GERN) COO Andrew J. Grethlein Sells 674,348 SharesJuly 26 at 4:55 PM | msn.comGeron stock gains 6% on updated guidelines for RyteloJuly 27, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 26 at 4:55 PM | finance.yahoo.comGeron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDSJuly 25 at 8:38 PM | finance.yahoo.comGeron Corporation (GERN) Stock Price, News, Quote & History - Yahoo FinanceJuly 25 at 10:37 AM | finance.yahoo.comGeron Corporation (GERN)July 24 at 9:49 AM | msn.comGeron stock dips as chief commercial officer departsJuly 24 at 4:49 AM | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Geron (GERN)July 27, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 23, 2024 | finance.yahoo.comGeron Corporation Announces Chief Commercial Officer to Depart at End of August 2024July 23, 2024 | marketwatch.comGeron Shares Drop as Chief Commercial Officer Set to Exit >GERNJuly 23, 2024 | msn.comGeron (GERN) to Report Q2 Earnings: What's in the Cards?July 20, 2024 | uk.finance.yahoo.com0IV3.IL,0P0001H56V,1198 (0IV3.IL)July 19, 2024 | benzinga.comGeron (NASDAQ:GERN) Stock Quotes, Forecast and News SummaryJuly 17, 2024 | americanbankingnews.comGeron Co. (NASDAQ:GERN) Sees Significant Decline in Short InterestJuly 11, 2024 | investorplace.com3 Under-$10 Biotech Stocks That Could Make You RichJuly 8, 2024 | investorplace.com3 Longevity Stocks to Buy for Anti-Aging BreakthroughsJune 13, 2024 | investorplace.comHow to Invest in Penny Stocks in 2024: 3 Best PicksSee More Headlines Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$6.93 High Stock Price Target$10.00 Low Stock Price Target$4.50 Potential Upside/Downside+48.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,130,000.00 Net Margins-38,730.00% Pretax Margin-38,729.81% Return on Equity-68.16% Return on Assets-47.26% Debt Debt-to-Equity Ratio0.03 Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual Sales$240,000.00 Price / Sales11,516.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book10.13Miscellaneous Outstanding Shares593,130,000Free Float574,746,000Market Cap$2.76 billion OptionableOptionable Beta0.48 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. John A. Scarlett M.D. (Age 73)Chairman of the Board, President & CEO Comp: $1.36MMs. Michelle J. Robertson (Age 57)Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Comp: $340.98kDr. Andrew J. Grethlein Ph.D. (Age 60)Executive VP & COO Comp: $827.01kMr. Scott SamuelsExecutive VP, Chief Legal Officer & Corporate SecretaryMs. Aron FeingoldVice President of Investor Relations & Corporate CommunicationsMs. Shannon Odam (Age 49)Senior VP & Chief People Officer Ms. Melissa A. Kelly Behrs (Age 60)Executive VP of Business Operations & Chief Alliance Officer Comp: $753.22kMr. Anil Kapur (Age 54)Executive VP of Corporate Strategy & Chief Commercial Officer Comp: $654.89kMr. Edward E. Koval (Age 62)Executive VP & Chief Business Officer Dr. Faye Feller M.D. (Age 41)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsChinook TherapeuticsNASDAQ:KDNYOrganogenesisNASDAQ:ORGOInozyme PharmaNASDAQ:INZYFoghorn TherapeuticsNASDAQ:FHTXZIOPHARM OncologyNASDAQ:ZIOPView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 415,883 shares on 7/26/2024Ownership: 0.340%Hennion & Walsh Asset Management Inc.Bought 253,857 shares on 7/20/2024Ownership: 0.043%Values First Advisors Inc.Bought 27,006 shares on 7/19/2024Ownership: 0.005%Baader Bank AktiengesellschaftBought 20,431 shares on 7/17/2024Ownership: 0.003%SG Americas Securities LLCSold 36,377 shares on 7/12/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions GERN Stock Analysis - Frequently Asked Questions How have GERN shares performed this year? Geron's stock was trading at $2.11 at the beginning of 2024. Since then, GERN shares have increased by 120.9% and is now trading at $4.66. View the best growth stocks for 2024 here. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) announced its earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The biopharmaceutical company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.15 million. Geron had a negative net margin of 38,730.00% and a negative trailing twelve-month return on equity of 68.16%. What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees. Who are Geron's major shareholders? Top institutional shareholders of Geron include Bank of New York Mellon Corp (0.34%), Hennion & Walsh Asset Management Inc. (0.04%), Values First Advisors Inc. and Baader Bank Aktiengesellschaft. Insiders that own company stock include John A Scarlett, Olivia Kyusuk Bloom, Elizabeth G O'farrell, Faye Feller and Andrew J Grethlein. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL) and Chesapeake Energy (CHKAQ). This page (NASDAQ:GERN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
